GIP and diabetes mellitus: Recent advances in antidiabetic therapy-including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual GIP/GLP-1 receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors-have transformed diabetes management by providing benefits beyond glycemic control, such as cardiovascular and renal protection, weight reduction, and improved quality of life.